← Leaderboards
Nicolas Mathey-Andrews
Harvard Medical School
$161,206
Attributed
$161,206
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $54.5K · FY2023–25$100K$75K$50K$25K$0
'23
'24
'25
Funding mix
By agency
NIH$161,206 · 1
By mechanism
F30$161,206 · 1
Top collaborators
No co-investigators on record.
Most similar at Harvard Medical School
Same institution · by research overlap
- Fred M. Winston$20,523,694
- Gerhard Wagner$49,510,293
- Arlene H Sharpe$68,359,602
- Marie-Claire Elisabeth Gauduin$15,247,447
- Carlos Federico Lopez$1,806,568
Others in their field
Other Rising Stars on “Cohort”
- Gary Mays · Axle Informatics, Llc$58,129,860
- Brian Zavertnik · Palantir Technologies, Inc.$37,240,166
- Joan Grand · Mitre Corporation$32,826,287
- Bridget Murphy · Broad Institute, Inc.$23,600,775
- Suma Babu · Massachusetts General Hospital$22,928,184
- Sabrina Paganoni · Massachusetts General Hospital$22,928,184
Research focus
CohortAdenocarcinomaAdvanced Malignant NeoplasmAdaptive Immune ResponseAntibodiesAntigen PresentationAntigensAntigen-Specific T CellsAnimalsAdaptive Immune SystemAnti-Tumor Immune ResponseBindingBioinformaticsBiological MarkersCancer CellCancer EtiologyCancer GenomeCancer ImmunotherapyCd8b1 GeneCd8-Positive T-LymphocytesCellsCessation Of LifeClinical PredictorsCommon Neoplasm
Grant awards (3)
Investigating splicing-derived antigens in the context of Rbm10-mutant lung adenocarcinoma$54,538
F30 · FY2025 · CA · contact PI
Investigating splicing-derived antigens in the context of Rbm10-mutant lung adenocarcinoma$53,974
F30 · FY2024 · CA · contact PI
Investigating splicing-derived antigens in the context of Rbm10-mutant lung adenocarcinoma$52,694
F30 · FY2023 · CA · contact PI